GSK Pulls Imus Ads…BUT, Only Until “Media Standards” Are Met
Within hours of my call for Glaxo to pull its Imus ads (see "Glaxo, Pull Your Imus Ads"), which I posted at around 6 AM this morning, I learn that GSK...
Glaxo, Pull Your Imus Ads!
The Wall Street Journal reports that several advertisers, including Pocter & Gamble, announced that are pulling their ad support of the Imus radio show. GlaxoSmithKline is another pharmaceutical company whose ads...
A Few Rules for Pharma Employee Blogging
My post yesterday (see "The Zubillaga Affair: Effect on the Prospects for Pharma Blogging" and " 'Round the Sphere: The Zubillaga Affair and Aftermath") seems to have hit a nerve.The premise...
The Zubillaga Affair: Effect on the Prospects for Pharma Blogging
The Pharma Blogosphere is all a twitter about an AstraZeneca internal Oncology newsletter that published a controversial analogy made by Mike Zubillaga, AZ's Mid-Atlantic regional sales director/oncology.What Mike said was:"Call Execution...
Botox Banality Not a Boon for TV Sitcoms
Despite extolling the ability to "express yourself" while under the influence of Botox in recent TV "reminder ads" -- which, BTW, go against the self-imposed industry ban on such ads --...
Web 2.0 Hates Sally
Sally Field is all over the TV these days hawking Boniva. One night she's talking about her own experience with osteoporosis and the next she's talking about "her friend."The FTC soon...
Celebrex Ad: Let’s Dive Deeper
Recently, Pfizer ran a long animated TV ad for Celebrex that made many claims within the 2 and a half minute running time. But were these claims accurately understood by viewers?...
The New Celebrex TV Ad: What Did You Learn?
Pfizer's new Celebrex TV ad, which aired last night for the first time during ABC's World News with Charles Gibson, was unique in several respects. But what did viewers learn from...
Device DTC: Imagine How Far It Will Go!
Like me, you probably have been seeing more ads on TV for medical devices like pacemakers and knee replacements. One ad from Stryker for a knee replacement caught my attention Sunday.In...
Kindler’s Refreshing View of Pharma’s Problems and His Job
Recently, I came across this Newsweek interview of Jeff Kindler, CEO of Pfizer. His candor is refreshing. I only reproduce bits and pieces here. I trust nothing was lost in translation.Q:...
